Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: We discuss alternative strategies to develop the chemotherapeutic agent based on targeting ErbB family ligands rather than their receptors. A phase I study of CRM197 for advanced ovarian cancer has already begun, which is the first approved trial of ErbB- ligand-targeted therapy. We also discuss clinical adaptations based on combination of CRM197 with other conventional chemotherapeutic agents.
|
Authors | Hiroshi Tsujioka, Fusanori Yotsumoto, Shoko Hikita, Taeko Ueda, Masahide Kuroki, Shingo Miyamoto |
Journal | Current opinion in obstetrics & gynecology
(Curr Opin Obstet Gynecol)
Vol. 23
Issue 1
Pg. 24-30
(Feb 2011)
ISSN: 1473-656X [Electronic] England |
PMID | 20966750
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Bacterial Proteins
- HBEGF protein, human
- Heparin-binding EGF-like Growth Factor
- Intercellular Signaling Peptides and Proteins
- Lysophospholipids
- CRM197 (non-toxic variant of diphtheria toxin)
- Epidermal Growth Factor
- Protein Serine-Threonine Kinases
- lysophosphatidic acid
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Bacterial Proteins
(therapeutic use)
- Cell Proliferation
(drug effects)
- Clinical Trials, Phase I as Topic
- Epidermal Growth Factor
(antagonists & inhibitors)
- Female
- Heparin-binding EGF-like Growth Factor
- Humans
- Intercellular Signaling Peptides and Proteins
(metabolism)
- Lysophospholipids
(metabolism)
- Ovarian Neoplasms
(drug therapy, metabolism, pathology)
- Protein Serine-Threonine Kinases
(metabolism)
- Signal Transduction
|